Diplomat Pharmacy (NYSE:DPLO) Downgraded to Strong Sell at ValuEngine

ValuEngine cut shares of Diplomat Pharmacy (NYSE:DPLO) from a sell rating to a strong sell rating in a report published on Monday, February 4th.

Several other equities research analysts also recently weighed in on the company. Lake Street Capital downgraded Diplomat Pharmacy from a buy rating to a hold rating and lowered their price target for the stock from $30.00 to $15.00 in a report on Tuesday, January 8th. William Blair downgraded Diplomat Pharmacy from an outperform rating to a market perform rating in a report on Monday, January 7th. Zacks Investment Research downgraded Diplomat Pharmacy from a hold rating to a strong sell rating in a report on Thursday, January 3rd. Robert W. Baird raised Diplomat Pharmacy from an underperform rating to a neutral rating and lifted their target price for the stock from $10.00 to $15.00 in a report on Friday, December 7th. Finally, Morgan Stanley decreased their target price on Diplomat Pharmacy from $20.00 to $18.00 and set an equal weight rating for the company in a report on Monday, December 3rd. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and two have given a buy rating to the stock. The stock has an average rating of Hold and a consensus price target of $13.78.

NYSE DPLO traded down $0.19 during trading on Monday, hitting $6.26. The company’s stock had a trading volume of 1,680,097 shares, compared to its average volume of 528,130. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.66 and a current ratio of 0.95. The company has a market cap of $466.18 million, a PE ratio of 7.45 and a beta of 0.98. Diplomat Pharmacy has a fifty-two week low of $5.56 and a fifty-two week high of $28.74.

Several institutional investors have recently added to or reduced their stakes in DPLO. Capital International Investors acquired a new stake in shares of Diplomat Pharmacy during the third quarter worth about $99,092,000. Frontier Capital Management Co. LLC raised its position in Diplomat Pharmacy by 84.1% during the third quarter. Frontier Capital Management Co. LLC now owns 3,535,217 shares of the company’s stock valued at $68,619,000 after acquiring an additional 1,614,645 shares in the last quarter. BlackRock Inc. raised its position in Diplomat Pharmacy by 17.0% during the third quarter. BlackRock Inc. now owns 8,464,251 shares of the company’s stock valued at $164,292,000 after acquiring an additional 1,228,490 shares in the last quarter. Bank of New York Mellon Corp raised its position in Diplomat Pharmacy by 97.5% during the fourth quarter. Bank of New York Mellon Corp now owns 1,682,590 shares of the company’s stock valued at $22,648,000 after acquiring an additional 830,436 shares in the last quarter. Finally, Matarin Capital Management LLC purchased a new position in Diplomat Pharmacy during the third quarter valued at approximately $13,536,000. 84.49% of the stock is owned by hedge funds and other institutional investors.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Recommended Story: Lock-Up Period Expiration

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply